Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02767531 · ClinicalTrials.gov registry record · Phase 2
Orlistat for the Treatment of Type I Hyperlipoproteinemia
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02767531: Completed Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
NCT02767531 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02767531, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Patients with Type I Hyperlipoproteinemia (T1HLP) have a rare form of hypertriglyceridemia marked by significant chylomicronemia and recurrent episodes of acute pancreatitis. T1HLP is caused by a deficiency of lipoprotein lipase or one of its cofactors. Many patients are a challenge to treat, as the only effective therapy available is an extremely low fat diet. This diet is exceedingly difficult to follow, and despite adherence, many patients still have chylomicronemia and develop acute pancreatitis. Specific Aim: To determine the efficacy of a gastric and pancreatic lipase inhibitor, Orlistat, in reducing serum triglyceride levels in patients with T1HLP.
Primary Outcome
Fasting blood samples were collected on three consequetive days at the end of each three month period. Mean values of the three days were calculated.
Interventions
- DRUG Orlistat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-12 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 2 |
What the finished NCT02767531 record still lists
NCT02767531 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Orlistat is the first listed.
NCT02767531 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02767531 about?
NCT02767531 is a clinical study titled "Orlistat for the Treatment of Type I Hyperlipoproteinemia". Patients with Type I Hyperlipoproteinemia (T1HLP) have a rare form of hypertriglyceridemia marked by significant chylomicronemia and recurrent episodes of acute pancreatitis. T1HLP is caused by a deficiency of lipoprotein lipase or one of its cofactors. Many patients are a challenge to treat, as the...
What is the current status of trial NCT02767531?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2015-12. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT02767531?
The interventions under investigation include: Orlistat (DRUG).
Who is sponsoring clinical trial NCT02767531?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02767531's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia